Liquid Biopsy Market: Global Industry Trends, Growth Drivers, and Future Outlook
The Liquid Biopsy Market is experiencing strong growth as healthcare providers increasingly adopt non-invasive diagnostic technologies for cancer detection, treatment monitoring, and personalized medicine. According to WiseGuyReports, the global market was valued at USD 9.9 billion in 2025 and is projected to reach USD 29.7 billion by 2035, representing a CAGR of 11.6% during the forecast period.
Liquid biopsy uses biological materials obtained from bodily fluids, particularly blood, to identify biomarkers such as circulating tumor DNA and circulating tumor cells. Its less-invasive nature compared with traditional tissue biopsy makes it attractive for repeated testing and real-time monitoring.
The oncology segment represents a major area of application, supported by the increasing prevalence of cancer and growing demand for early detection. Technological developments in next-generation sequencing and digital PCR are improving the sensitivity and specificity of liquid biopsy testing.
North America currently maintains a leading position because of advanced healthcare infrastructure, research capabilities, and adoption of precision medicine. Asia-Pacific is also emerging as a promising region due to increasing healthcare expenditure and growing awareness of advanced diagnostics.
Overall, technological innovation, rising cancer prevalence, and demand for personalized treatment are expected to support continued expansion of the global Liquid Biopsy Market.